Winners of the 16th Pharma Awards

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.
CPHI Worldwide has announced the winners of the prestigious 2019 CPHI Pharma Awards – celebrating the industry’s top innovators, performers and outstanding achievements across 13 categories, spanning the entire industry supply chain. The winners have been recognised for delivering excellence in pharma and were unveiled during an invitation-only ceremony on the opening evening of CPHI Worldwide in Frankfurt.
The prestigious ‘CEO of the Year’ award has been bestowed upon Dr Ge Li, Founder, Chairman and CEO of WuXi AppTec, who was chosen for his significant contribution to the global biopharma R&D industry. Under his leadership, WuXi AppTec has become a highly respected contributor to global healthcare innovation. The company is enabling more than 3,700 customers and partners in more than 30 countries by offering open-access capabilities and services, accelerating the discovery and development of new medicines for patients around the world.
For the second time in 3 years, Cambrex was awarded the ‘API Development’ category for their Crystallisation Screening and Process Development Service. The service has bridged the gap between the bench and manufacturing plat, providing controlled, robust and scalable crystallization processes. Hovione received a ‘highly commended’ acknowledgement for their Process Ranking of Inputs from Manufacturing (PRIME).
John Chiminski, Chair and CEO at Catalent Pharma Solutions, won the ‘Lifetime Achievement’ award for his accomplishments spanning more than three decades. These include the last 10 years at Catalent, during which time the company has become a true benchmark of advanced delivery technologies, development, and manufacturing solutions.
The ‘Formulation’ award was given to Nanoform for its controlled expansion of supercritical solutions (CESS). Spraying Systems Co./Fluid Air Inc. were bestowed with the ‘Manufacturing Technology and Equipment’ award for their PolarDry’ – the Cooler Technology. Cited as the future of spray drying, it utilises electrostatic technology to prevent against API loss, degradation, and denaturalisation.
Univercells received the ‘Bioprocessing and Manufacturing’ award in recognition of its NevoLine Platform, which is a bioproduction system for vaccines. The ‘Regulatory Procedures and Compliance’ prize was given to Merck Healthcare KGaA for ‘Project SARA’ (Smart Assistant for Regulatory Affairs).
The ‘Analysis, Testing, and Quality Control’ category was claimed by MedPharm for pioneering the regulatory approval of topical products using in vitro bioequivalence. MedPharm is the first contract research organisation to gain regulatory approval using in vitro models to demonstrate the bioequivalence of a generic formulation compared to the originator.
SCHOTT Pharmaceutical Systems and W.L. Gore & Associates received the ‘Packaging’ award for its syriQ BioPure – a silicone-free syringe – whilst Hoffmann Neopac was highly commended for their STYLO Spatula applicator.
The winner of the ‘Pharma Service Company of the Year Award’ is Lonza Pharma & Biotech. The company is recognised for its integrated global services offering that spans the pharmaceutical, biotech, consumer health and specialty chemicals market.
In ‘Contract Services and Outsourcing’ Nanopharm Ltd – an Aptar Pharma company – was selected as the winner for SmartTrack, with CMAC being highly commended for their CMAC National Facility.
Finally, the award for ‘Drug Delivery and Devices’ was given to Phillips-Medisize for its Connected Health Platform, and the ‘Supply Chain, Logistics and Distribution’ category was given to Kemiex AG.
Tara Dougal, Head of Content at Informa, commented: “The judges noted that this year our entries possessed an extremely high standard. All of the finalists would have made outstanding winners in previous years. On behalf of CPHI Worldwide, I would like to extend my congratulations to all the winners and commend all of the finalists. What you are doing is of tremendous benefit to the industry, but more importantly, it is also directly contributing to improved patient experiences globally.”
Related News
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance